Samsung Bioepis Doubles Profits After European Ustekinumab Debut

Sales Up By More Than Half In 2024 As Major US Launches Planned For H1

 
• By Dave Wallace
  
Samsung Bioepis enjoyed an uptick in results for 2024 (Shutterstock)

More from Earnings

More from Generics Bulletin